Clinical trials: Intermediate to High Risk of HCC
Chronic Hepatitis B, Intermediate to High Risk of HCC
A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients
China's new cases and deaths of hepatocellular carcinoma (HCC) rank first in the world. hepatocellular carcinoma is the third most morbid, second-most mortal malignancy in China.
- Trial name
- NCT05671315
- Testing
- Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue, Nucleos(t)ide analogue
- Where
- 9 sites in China
- Volunteers
- 267 people
- Sponsor
- Qing XIe